Ultra-Low-Dose CT Scans May Help Early Detection Of Pneumonia

Updated Mar 19, 2025 | 09:20 AM IST

SummaryCT scans are the gold standard for detecting pneumonia but there are concerns regarding the risk posed by repeated exposure to radiation.
Ultra-Low-Dose CT Scans May Detect Pneumonia in At-Risk Patients

Credit: Canva

Low-dose CT chest scans could help detect pneumonia in at-risk patients while exposing them to only small amounts of radiation, a new study has found. The research, published in Radiology: Cardiothoracic Imaging, shows that ultra-low-dose scans can effectively detect pneumonia in patients with compromised immune systems, enabling doctors to treat the infection before it becomes life-threatening. According to the researchers, these scans expose patients to just 2% of the radiation dose used in a standard CT scan.

"This study paves the way for safer, AI-driven imaging that reduces radiation exposure while preserving diagnostic accuracy,” lead researcher Dr Maximiliano Klug, a radiologist with the Sheba Medical Center in Ramat Gan, Israel, said in a news release. He added that CT scans are the gold standard for detecting pneumonia but there are concerns regarding the risk posed by repeated exposure to radiation. There is a solution- ultra-low-dose CT scan. However, the problem is that these scans can be grainy and hard to read, researchers said.

Study Gives Solution To This

To overcome that, Klug's team developed an AI program that could help "de-noise" low-dose scans, making them sharper and easier to read. Between September 2020 and December 2022, 54 patients with compromised immune systems who had fevers underwent a pair of chest CT scans -- a normal dose scan and an ultra-low-dose scan. The AI program cleaned up the low-dose scan, and then both sets of images were given to a pair of radiologists for assessment. Radiologists had 100% accuracy in detecting pneumonia and other lung problems with the AI-cleaned low-dose scans, but 91% to 98% accuracy in examining the scans that hadn’t been improved through AI, results show.

"This pilot study identified infection with a fraction of the radiation dose," Klug said. "This approach could drive larger studies and ultimately reshape clinical guidelines, making denoised ultra-low dose CT the new standard for young immunocompromised patients.

How Can You Detect Pneumonia?

Pneumonia is a lung infection that causes the air sacs in the lungs to fill with fluid or pus and can be caused by bacteria, viruses, or fungi. The symptoms can range from milk to severe, which includes:

Coughing with or without cough

Fever

Chills

Trouble breathing

Chest pain, especially when breathing deeply or coughing

Sweating or chills

Rapid heart rate

Loss of appetite

Bluish skin, lips, and nails

Confusion.

How to detect Pneumonia in coughing newborns and toddlers?

Pneumonia can severely affect newborns and young children as their lungs are comparatively more sensitive. As per Dr Goyal, young children can cough for various reasons including seasonal infections and tonsillitis, which is very common in this age group. But if they look visibly irritable and have poor sleep patterns, then parents must reach out to an expert. "I am not saying that parents must visit a hospital but any local paediatrician would be able to detect pneumonia in your kid.

End of Article

Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?

Updated Nov 18, 2026 | 09:34 AM IST

SummarySELLAS Life Sciences recently announced findings from their late-stage clinical trial in which they tested an experimental cancer vaccine for acute myeloid leukemia (AML).
Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?

Credit: AI image

Amid growing research in vaccination for different cancers, an experimental cancer vaccine cut the risk of death by 41% in patients with acute myeloid leukemia (AML) in a late-stage clinical trial.

Showing promise in treating the aggressive blood cancer, the findings have given hope to patients whose cancer has returned after treatment and those who have limited options.

The vaccine, called galinpepimut-S (GPS), is being developed by US-based pharma company SELLAS Life Sciences. Results from the Phase 3 REGAL trial showed that patients who received the vaccine lived longer than those given the next best available treatment.

What Is Acute Myeloid Leukemia?

Also read: Health Canada Warns Against Faulty Radon Detectors: How The Invisible Gas In Your Home May Cause Lung Cancer

Acute myeloid leukemia is an aggressive blood cancer that begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells. It develops when abnormal immature blood cells multiply rapidly and interfere with the production of healthy red blood cells, white blood cells and platelets.

Common symptoms include persistent fatigue, fever, frequent infections, easy bruising, unusual bleeding and breathlessness.

Treatment usually involves chemotherapy, specific medicines in eligible patients and in some cases, stem-cell transplantation. AML can return after treatment, making it difficult to achieve remission.

What Did The Trial Find?

Also read: World Cervical Cancer Elimination Day 2026: WHO Calls For HPV Vaccination, Screening & Early Treatment

The trial involved 126 patients who had achieved remission after treatment but were unable to undergo a stem-cell transplant.

According to the findings, the vaccine reduced the risk of death by 41%. Patients receiving GPS had a median overall survival of 24 months, compared to 14.7 months among those receiving standard treatment. The results also showed a hazard ratio of 0.59 and a p-value of 0.035.

SELLAS plans to discuss the findings with the US Food and Drug Administration (FDA), preparing to submit an application for approval in the first half of 2027.

How Does The Leukemia Vaccine Work?

Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Unlike preventive vaccines, GPS is a therapeutic cancer vaccine. It is developed to help immune system identify and destroy residual cancer cells in the body after treatment.

The vaccine targets a protein called Wilms' Tumour 1 (WT1), which is found in more than 95% of people with AML, according to Memorial Sloan Kettering Cancer Center (MSK), where the vaccine was developed.

GPS contains synthetic peptides, which are short chains of amino acids derived from the WT1 protein. These peptides help the immune system to produce specialised T cells that recognise and attack cancer cells carrying WT1.

In simple terms, the vaccine trains the immune system to identify leftover cancer cells that may be too small to detect through routine testing but could eventually cause cancer recurrence.

Unlike personalised cancer vaccines that are manufactured using an individual patient's tumour, GPS is an off-the-shelf vaccine that can be used in multiple patients.

Side Effects Of GPS

GPS was generally tolerated well in the Phase 3 trial as no safety concerns were identified. Most side effects were mild to moderate. Reactions at injection sites were among the most commonly reported side effects.

The company, however, has only announced topline results. The detailed findings from the trial's secondary endpoints related to relapse-free and leukemia-free survival, will be presented at a future medical conference.

If the findings are supported by regulatory authorities, GPS could become a new treatment option for patients whose AML has relapsed and those who cannot opt for a stem-cell transplant.

End of Article

Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond

Updated Nov 18, 2026 | 08:53 AM IST

SummaryThe Pan American Health Organization (PAHO) recently announced that the United States, Mexico and Bolivia have lost their measles-free status as they failed to interrupt transmission over a period of 12 months.
Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond

Credit: AI image

The United States is not the only country to lose its measles elimination status this year. Mexico and Bolivia have also lost the status after the highly contagious virus continued spreading for more than 12 months, according to the Pan American Health Organization (PAHO).

The decision was formally announced on November 17, 2026 by PAHO's independent Regional Monitoring and Re-Verification Commission, which reviewed measles data from 47 countries and territories across the Americas.

The United States had maintained its measles elimination status since 2000, while Mexico and Bolivia had also previously interrupted sustained local transmission. The latest development marks a setback in efforts to control a disease that can be prevented through vaccination.

The announcement comes as measles cases continue to rise across the region. As of November 13, 2026, the Americas had reported 58,213 confirmed cases and 82 deaths, compared with 12,806 cases during the same period in 2025.

Three Countries In Americas Lose Measles-Free Status

Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

According to PAHO, a country loses its measles elimination status when the same measles virus genotype and lineage circulates continuously within its borders for at least 12 months. This indicates that the virus has re-established endemic transmission rather than appearing only through isolated cases imported from other countries.

According to PAHO, the sustained transmission periods in the three countries began on different dates:

  • United States: The outbreak began on January 20, 2025, reaching the 12-month threshold on January 20, 2026.
  • Mexico: The outbreak began on February 1, 2025, reaching the one-year mark on February 1, 2026.
  • Bolivia: The outbreak began on April 16, 2025, marking one year of continued transmission on April 16, 2026.

Losing elimination status does not mean that measles is spreading everywhere within these countries. It means that the same virus lineage has continued circulating locally for at least a year.

The Americas had previously lost its regional measles elimination status in November 2025, after Canada reported to have sustained transmission for more than 12 months. The region had first eliminated measles in 2016 and regained that achievement in 2024 after stopping transmission in Venezuela and Brazil.

What Did HHS Secretary Robert F Kennedy Jr And CDC Chief Dr Erica Schwartz Say?

Also read: US Loses Measles Elimination Status After 26 Years: What Does It Mean?

After PAHO's announcement, US Health and Human Services Secretary Robert F. Kennedy Jr and Centers for Disease Control and Prevention (CDC) Director Dr Erica Schwartz issued separate statements.

Kennedy said the administration would continue working to control outbreaks and restore the country's elimination status.

"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," he said in a statement. He also expressed his support for vaccination, adding, "I continue to recommend MMR vaccination as the most effective way to prevent measles."

Kennedy attributed gaps in childhood immunisation to disruptions during the COVID-19 pandemic which affected routine vaccination programmes in the US and other countries.

He also said that approximately $100 million in additional CDC funding has been provided since August to strengthen measles prevention and outbreak response. The funding is intended to support state and local health departments, improve surveillance and help close vaccination gaps.

CDC Director Dr Schwartz said the loss of the designation would not change the agency's approach to controlling the disease.

"The measles elimination designation is not what protects Americans. Vaccination does. We know where transmission is occurring and we've invested $100 million in state and local health departments to reach those communities," she said.

"Losing a designation doesn't mean we abandon an evidence-based approach. It means we remain focused on stopping outbreaks."

Also read: RFK Jr's Vaccine Controversy: What His Samoa Trip Has To Do With 83 Measles Deaths

Measles Resurgence In The Americas

The latest PAHO figures highlight the scale of the resurgence. The region recorded more than four times as many confirmed measles cases by November 13, 2026 as during the corresponding period in 2025.

Mexico has reported more than 13,900 confirmed cases so far in 2026, the highest annual total since the 1989-90 epidemic. The US has recorded more than 5,400 cases and 10 deaths, its highest in more than 35 years. Bolivia has reported more than 100 cases.

Amid the resurgence, a CDC report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.

Measles is among the most contagious infectious diseases. One infected person can transmit the virus to as many as 18 people who are susceptible to infection.

The disease typically causes fever, cough, a runny nose, red and watery eyes, followed by a characteristic skin rash. However, it can also lead to serious complications, including pneumonia, brain inflammation (encephalitis), blindness and death. It can also weaken the immune system for months after infection.

Can The Countries Regain Measles Elimination Status?

PAHO expects the US, Mexico and Bolivia to submit plans outlining how they plan to interrupt transmission and strengthen measles vaccination and surveillance.

The organisation has called on countries across the Americas to achieve and maintain at least 95% coverage with both doses of the measles vaccine.

The MMR vaccine, which protects against measles, mumps and rubella, remains the most effective way to prevent measles.

End of Article

US FDA Approves First Drug To Cut Death Risk By 55% In Niemann-Pick Patients: What Is The Rare Disease?

Updated Nov 18, 2026 | 07:02 AM IST

SummaryNiemann-Pick disease type C (NPC) is a rare inherited disorder that affects the body's ability to process cholesterol. Lembaz addresses this underlying cause, extending life expectancy.
US FDA Approves First Drug To Cut Death Risk By 55% In Niemann-Pick Patients: What Is The Rare Disease?

Credit: AI image

The US Food and Drug Administration (FDA) has granted approval to a new drug that could help patients with a rare and life-threatening genetic disorder live longer. The treatment, Lembaz (adrabetadex), is the first drug proven to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C (NPC).

Announced on November 17, 2026, the approval marks an important development for families affected by the rare disease, which causes progressive neurological damage and can significantly shorten life expectancy.

Lembaz is approved for adults and children weighing at least 7 kg (approximately 15 pounds) whose neurological symptoms began before the age of six. It is administered as an injection directly into the fluid surrounding the spinal cord, a procedure known as an intrathecal injection, every two weeks.

"For the first time, there is a treatment shown to help adults and children with this serious disease live longer," said Acting FDA Commissioner Kyle Diamantas.

Lembaz Reduces Risk Of Death By 55% In Niemann-Pick Patients

Also read: Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

The FDA's approval was based on data from 36 patients treated with Lembaz across three clinical studies. Their outcomes were compared to an external control group of patients who had not received the treatment.

The analysis found that patients who received Lembaz had a 55% lower risk of death compared to the control group.

The median overall survival was 8.5 years among patients treated with Lembaz compared to 4.9 years in the control group.

The benefit was observed regardless of whether patients were also receiving miglustat, another medicine used to manage NPC.

What Is Niemann-Pick Disease Type C?

Also read: Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?

Niemann-Pick disease type C is a rare inherited disorder that affects the body's ability to process cholesterol and other fatty substances inside cells.

The condition is caused by changes in either the NPC1 or NPC2 gene. These genes produce proteins that help move cholesterol and other lipids within cells. When these proteins do not function properly, fatty substances accumulate inside cells, affecting organs like liver, spleen and brain. Over time, this causes progressive damage to the nervous system.

Patients may experience difficulties with movement, balance, coordination, speech and swallowing. Some may also face seizures, cognitive difficulties and problems controlling eye movements.

The disease affects approximately one in 150,000 people, according to the FDA. Its symptoms and severity can vary depending on when the disease begins.

Infantile-Onset Niemann-Pick Disease Can Be Severe

Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Infantile-onset NPC refers to cases in which neurological symptoms start before the age of six. These patients experience a more aggressive disease as they face rapid progressive neurological deterioration and a shorter life expectancy.

As the disease advances, children may gradually lose the ability to walk, speak and swallow independently. Difficulties with swallowing can also increase the risk of respiratory complications.

There is currently no cure for NPC, making treatments that can slow disease progression or improve survival important.

More About Lembaz

Lembaz contains adrabetadex, a cyclodextrin-based medicine made to address the underlying cholesterol processing defect in NPC.

In simple terms, the drug helps move cholesterol trapped inside cells, especially brain cells, so that it can be transported to areas where it is needed.

By targeting this underlying problem, the treatment aims to reduce the cellular damage that comes with the disease.

According to the FDA, hearing impairment, including permanent hearing loss, could be one of the side effects of Lembaz. Hence, patients must undergo hearing assessments before starting the drug and regularly throughout the course.

Other common side effects include balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhoea, nausea and cough.

End of Article